Form 4: BioCryst Pharmaceuticals Director Vincent Milano Buys $93,750 in Company Stock
SEC Form 4 Filing
Director Vincent Milano increased his holdings in BioCryst Pharmaceuticals by purchasing 15,000 shares at an average price of $6.25 on May 20, 2024.
Summary
- On May 20, 2024, Vincent Milano, a director of BioCryst Pharmaceuticals Inc. (BCRX), purchased 15,000 shares of common stock.
- The purchase was made at a weighted average price of $6.25 per share, with individual transactions ranging from $6.23 to $6.25.
- Following the transaction, Milano's direct ownership in BioCryst Pharmaceuticals increased to 66,997 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the transaction is relatively small and may not have a significant impact.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider buying is often monitored by investors as an indicator of management's confidence in the company's prospects. It can be a positive signal, especially when compared to insider selling.
Stakeholder Impact
- The purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of transaction: Vincent Milano purchased 15,000 shares of BioCryst Pharmaceuticals. |
| 05/22/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.